Renaissance Technologies (RenTech)'s HALO Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 562,711 shares of Halozyme Therapeutics, Inc. (HALO) worth $37.87 M, representing 0.06% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in HALO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 1.22 M shares. Largest reduction occurred in Q1 2020, reducing 895,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -437,498 | Reduce 43.74% | 562,711 | $67.30 |
| Q3 2025 | +661,600 | Add 195.39% | 1 M | $73.34 |
| Q2 2025 | +218,599 | Add 182.15% | 338,609 | $52.02 |
| Q1 2025 | +93,900 | Add 359.63% | 120,010 | $63.81 |
| Q4 2024 | -229,170 | Reduce 89.77% | 26,110 | $47.81 |
| Q3 2024 | -122,300 | Reduce 32.39% | 255,280 | $57.24 |
| Q2 2024 | -53,800 | Reduce 12.47% | 377,580 | $52.36 |
| Q1 2024 | +238,000 | Add 123.07% | 431,380 | $40.68 |
| Q4 2023 | +87,700 | Add 82.99% | 193,380 | $36.96 |
| Q3 2023 | +71,600 | Add 210.09% | 105,680 | $38.20 |
| Q2 2023 | -61,061 | Reduce 64.18% | 34,080 | $0.04 |
| Q1 2023 | -46,500 | Reduce 32.83% | 95,141 | $0.04 |
| Q4 2022 | -216,659 | Reduce 60.47% | 141,641 | $0.06 |
| Q3 2022 | -126,900 | Reduce 26.15% | 358,300 | $39.54 |
| Q2 2022 | +277,500 | Add 133.61% | 485,200 | $44.00 |
| Q1 2022 | +81,700 | Add 64.84% | 207,700 | $39.88 |
| Q4 2021 | -27,200 | Reduce 17.75% | 126,000 | $40.21 |
| Q3 2021 | +153,200 | New Buy | 153,200 | $40.68 |
| Q2 2021 | -673,700 | Sold Out | 0 | $0.00 |
| Q1 2021 | +145,571 | Add 27.56% | 673,700 | $41.69 |
| Q4 2020 | +429 | Add 0.08% | 528,129 | $42.71 |
| Q3 2020 | -480,500 | Reduce 47.66% | 527,700 | $26.28 |
| Q2 2020 | +684,800 | Add 211.75% | 1.01 M | $26.81 |
| Q1 2020 | -895,200 | Reduce 73.46% | 323,400 | $17.99 |
| Q4 2019 | +1.22 M | New Buy | 1.22 M | $17.73 |
| Q3 2019 | -458,600 | Sold Out | 0 | $0.00 |
| Q2 2019 | -290,800 | Reduce 38.80% | 458,600 | $17.18 |
| Q1 2019 | +444,800 | Add 146.03% | 749,400 | $16.10 |
| Q4 2018 | -286,000 | Reduce 48.43% | 304,600 | $14.63 |
| Q3 2018 | -287,800 | Reduce 32.76% | 590,600 | $18.17 |
| Q2 2018 | -15,000 | Reduce 1.68% | 878,400 | $16.87 |
| Q1 2018 | +156,800 | Add 21.29% | 893,400 | $19.59 |
| Q4 2017 | +736,600 | New Buy | 736,600 | $20.26 |
| Q1 2017 | -14,700 | Sold Out | 0 | $0.00 |
| Q4 2016 | -85,300 | Reduce 85.30% | 14,700 | $9.86 |
| Q3 2016 | +100,000 | New Buy | 100,000 | $12.08 |
| Q2 2016 | -375,000 | Sold Out | 0 | $0.00 |
| Q1 2016 | +375,000 | New Buy | 375,000 | $9.47 |
| Q4 2015 | -11,600 | Sold Out | 0 | $0.00 |
| Q3 2015 | -146,000 | Reduce 92.64% | 11,600 | $13.45 |
| Q2 2015 | -223,200 | Reduce 58.61% | 157,600 | $22.58 |
| Q1 2015 | +303,100 | Add 390.09% | 380,800 | $14.28 |
| Q4 2014 | +77,700 | New Buy | 77,700 | $9.65 |
| Q3 2014 | -289,062 | Sold Out | 0 | $0.00 |
| Q2 2014 | +153,662 | Add 113.49% | 289,062 | $9.88 |
| Q1 2014 | -164,600 | Reduce 54.87% | 135,400 | $12.70 |
| Q4 2013 | +300,000 | New Buy | 300,000 | $14.99 |
Renaissance Technologies (RenTech)'s Halozyme Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Halozyme Therapeutics, Inc. (HALO) in Q4 2013, acquiring 300,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Halozyme Therapeutics, Inc. (HALO) for 47 quarters since Q4 2013.
Renaissance Technologies (RenTech)'s largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q4 2019, adding 1,218,600 shares worth $21.61 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 562,711 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $37.87 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.06% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Halozyme Therapeutics, Inc. (HALO) was 1,218,600 shares, as reported at the end of Q4 2019.